Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan Weiss

Showing results (121-130 of 138) with videos related to

Pageof 14
Sort By:
American Journal of Obstetrics and Gynecology|June 30, 2012
Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18Mary E Norton, Herb Brar, Jonathan Weiss, et al.
Blood|December 9, 2024
The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomasNermin Kady, Suhaib Abdelrahman, Ahmar M Rauf, et al.
Cancer Research|January 28, 2010
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutationMartin L Sos, Haridas B Rode, Stefanie Heynck, et al.
Cancer Research|March 3, 2025
Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFRMartin L Sos, Mirjam Koker, Barbara A Weir, et al.
American Journal of Clinical Dermatology|August 3, 2005
Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trialSewon Kang, Wilma Bergfeld, Alice B Gottlieb, et al.
Cancer Research|April 9, 2009
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRMartin L Sos, Mirjam Koker, Barbara A Weir, et al.
Blood|April 15, 2024
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trialMoritz Fürstenau, Adam Giza, Jonathan Weiss, et al.
The Journal of Molecular Diagnostics : JMD|July 7, 2023
Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid TumorsHarrison K Tsai, Tasos Gogakos, Va Lip, et al.
The American Journal of Pathology|November 3, 2023
Specific Polo-Like Kinase 1 Expression in Nodular Lymphocyte-Predominant Hodgkin Lymphoma Suggests an Intact Immune Surveillance ProgramJonathan Weiss, Kathryn Gibbons, Vida Ehyaee, et al.
Blood|November 10, 2023
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNAJan-Michel Heger, Julia Mattlener, Jessica Schneider, et al.
Pageof 14

Showing results (121-130 of 138) with videos related to

Sort By:
Pageof 14
American Journal of Obstetrics and Gynecology|June 30, 2012
Non-Invasive Chromosomal Evaluation (NICE) Study: results of a multicenter prospective cohort study for detection of fetal trisomy 21 and trisomy 18Mary E Norton, Herb Brar, Jonathan Weiss, et al.
Blood|December 9, 2024
The GATA-3-dependent transcriptome and tumor microenvironment are regulated by eIF4E and XPO1 in T-cell lymphomasNermin Kady, Suhaib Abdelrahman, Ahmar M Rauf, et al.
Cancer Research|January 28, 2010
Chemogenomic profiling provides insights into the limited activity of irreversible EGFR Inhibitors in tumor cells expressing the T790M EGFR resistance mutationMartin L Sos, Haridas B Rode, Stefanie Heynck, et al.
Cancer Research|March 3, 2025
Editor's Note: PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFRMartin L Sos, Mirjam Koker, Barbara A Weir, et al.
American Journal of Clinical Dermatology|August 3, 2005
Long-term efficacy and safety of tretinoin emollient cream 0.05% in the treatment of photodamaged facial skin: a two-year, randomized, placebo-controlled trialSewon Kang, Wilma Bergfeld, Alice B Gottlieb, et al.
Cancer Research|April 9, 2009
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFRMartin L Sos, Mirjam Koker, Barbara A Weir, et al.
Blood|April 15, 2024
Acalabrutinib, venetoclax, and obinutuzumab in relapsed/refractory CLL: final efficacy and ctDNA analysis of the CLL2-BAAG trialMoritz Fürstenau, Adam Giza, Jonathan Weiss, et al.
The Journal of Molecular Diagnostics : JMD|July 7, 2023
Outlier Expression of Isoforms by Targeted or Total RNA Sequencing Identifies Clinically Significant Genomic Variants in Hematolymphoid TumorsHarrison K Tsai, Tasos Gogakos, Va Lip, et al.
The American Journal of Pathology|November 3, 2023
Specific Polo-Like Kinase 1 Expression in Nodular Lymphocyte-Predominant Hodgkin Lymphoma Suggests an Intact Immune Surveillance ProgramJonathan Weiss, Kathryn Gibbons, Vida Ehyaee, et al.
Blood|November 10, 2023
Entirely noninvasive outcome prediction in central nervous system lymphomas using circulating tumor DNAJan-Michel Heger, Julia Mattlener, Jessica Schneider, et al.
Pageof 14